Ticker Details
Exelixis, Inc. Common Stock Exelixis Inc is a biotechnology company. It is involved in discovery, development, and commercialization of new medicines for people with cancer. The Cabometyx product generates maximum revenue for the company.
IPO Date:	May 1, 2000
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$12.89B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.27 | 2.19%
Avg Daily Range (30 D):	$0.79 | 1.71%
Avg Daily Range (90 D):	$0.66 | 1.50%

Institutional Daily Volume
Avg Daily Volume:	2.07M
Avg Daily Volume (30 D):	2.18M
Avg Daily Volume (90 D):	2.19M

Trade Size
Avg Trade Size (Sh.):	152
Avg Trade Size (Sh.) (30 D):	56
Avg Trade Size (Sh.) (90 D):	60

Institutional Trades
Total Institutional Trades:	12,789
Avg Institutional Trade:	$3.07M
Avg Institutional Trade (30 D):	$5.08M
Avg Institutional Trade (90 D):	$5.56M
Avg Institutional Trade Volume:	.16M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$7.57M
Avg Closing Trade (30 D):	$20.41M
Avg Closing Trade (90 D):	$21.65M
Avg Closing Volume:	337.04K

News

Apr 21, 2026 @ 5:42 PM Why Is Merck Stock Falling Tuesday? Source: Vandana Singh

Mar 18, 2026 @ 12:30 PM The Best Healthcare Stocks to Buy With $50 Right N... Source: Prosper Junior Bakiny

Feb 28, 2026 @ 9:37 AM 3 Reasons Exelixis Stock Could Deliver Marketâ€... Source: James Halley

Jan 15, 2026 @ 11:44 AM InSilico Lands Drug Discovery Deal After Hong Kong... Source: Bamboo Works

Jan 8, 2026 @ 10:15 AM 2 Healthcare Stocks to Buy for 2026 and Beyond Source: Prosper Junior Bakiny

Financials
	TTM	Q1 2027	Q3 2026
Basic EPS		$.81	$.72
Diluted EPS		$.79	$.69
Revenue		$610.81M	$597.76M
Gross Profit		$590.86M	$579.18M
Net Income / Loss		$210.47M	$193.58M
Operating Income / Loss		$251.34M	$236.54M
Cost of Revenue		$19.95M	$18.57M
Net Cash Flow		$-256.34M	$211.87M
PE Ratio